



THE UNIVERSITY *of* EDINBURGH

Edinburgh Research Explorer

Progression-free survival as surrogate endpoint for overall survival in clinical trials of HER2-targeted agents in HER2-positive metastatic breast cancer

Citation for published version:

Michiels, S, Pugliano, L, Marguet, S, Grun, D, Barinoff, J, Cameron, D, Cobleigh, M, Di Leo, A, Johnston, S, Gasparini, G, Kaufman, B, Marty, M, Nekjudova, V, Paluch-Shimon, S, Penault-Llorca, F, Slamon, D, Vogel, C, Von Minckwitz, G, Buyse, M & Piccart, M 2016, 'Progression-free survival as surrogate endpoint for overall survival in clinical trials of HER2-targeted agents in HER2-positive metastatic breast cancer', *Annals of Oncology*. <https://doi.org/10.1093/annonc/mdw132>

Digital Object Identifier (DOI):

[10.1093/annonc/mdw132](https://doi.org/10.1093/annonc/mdw132)

Link:

[Link to publication record in Edinburgh Research Explorer](#)

Document Version:

Peer reviewed version

Published In:

Annals of Oncology

Publisher Rights Statement:

This article has been accepted for publication in The Annals of Oncology 2016 Published by Oxford University Press.

General rights

Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy

The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.



Progression-free survival as surrogate endpoint for overall survival in clinical trials of HER2-targeted agents in HER2-positive metastatic breast cancer

S. Michiels^{1,2,3,4}, L. Pugliano^{4,5}, S. Marguet¹, D. Grun⁴, J. Barinoff⁶, D. Cameron⁷, M. Cobleigh⁸, A. Di Leo⁹, S. Johnston¹⁰, G. Gasparini¹¹, B. Kaufman¹², M. Marty¹³, V. Nekjudova¹⁴, S. Paluch-Shimon¹², F. Penault-Llorca¹⁵, D. Slamon¹⁶, C. Vogel¹⁷, G. von Minckwitz¹⁴, M. Buyse¹⁸, M. Piccart^{4,5}

¹Service de Biostatistique et d'Epidémiologie, Gustave Roussy, Villejuif, France;

²Université Paris-Sud, Université Paris-Saclay, UVSQ, CESP, INSERM, Villejuif, France;

³Plateforme Ligue nationale contre le cancer de méta-analyse en oncologie, Gustave Roussy, Villejuif, France

⁴Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium;

⁵Breast International Group (BIG), Brussels, Belgium;

⁶Agaplesion Markus Krankenhaus, Frankfurt am Main, Germany;

⁷University of Edinburgh, Edinburgh, UK;

⁸Rush University Medical Center, Chicago, Illinois, USA;

⁹Medical Oncology Unit, Hospital of Prato, Istituto Toscano Tumori, Prato, Italy;

¹⁰Royal Marsden Hospital, London, UK;

¹¹Scientific Direction, IRCCS National Cancer Research Centre "Giovanni Paolo II" Bari, Italy;

¹²The Institute of Breast Oncology, Sheba Medical Center, Tel Hashomer, Israel;

¹³Maladies du Sein, Saint Louis Hospital, APHP, Paris, France;

¹⁴German Breast Group, GBG ForschungsGmbH, Neu-Isenburg, Germany;

¹⁵Department of Pathology, Centre Jean Perrin, EA 4233, University of Auvergne, Clermont-Ferrand, France;

¹⁶Jonsson Comprehensive Cancer Center, University of California–Los Angeles, Los Angeles, CA, USA;

¹⁷University of Miami School of Medicine, Comprehensive Cancer Research Group Inc, Columbia Cancer Research Network of Florida, Miami, Florida, USA;

¹⁸IDDI, Louvain-la-Neuve, Hasselt University, Hasselt, Belgium

Results were presented at the ASCO Annual meeting 2013.

Contacting author :

Dr. Stefan Michiels

Service de Biostatistique et d'Epidémiologie

Gustave Roussy, B2M RDC

114 rue Edouard Vaillant

94805 Villejuif cedex

France

stefan.michiels@gustaveroussy.fr

Tel +33 (0)1 42 11 41 44

Abstract (298)

Background: The gold standard endpoint in randomized clinical trials in metastatic breast cancer is overall survival. Although therapeutics have been approved based on progression-free survival, its use as a primary endpoint is controversial. We aimed to assess to what extent progression-free survival may be used as a surrogate for overall survival in randomized trials of anti-HER2 agents in HER2+ metastatic breast cancer.

Methods: Eligible trials accrued HER2+ metastatic breast cancer patients in 1992-2008. A correlation approach was used: at the individual level, to estimate the association between investigator-assessed progression-free and overall survival using a bivariate model and at the trial level, to estimate the association between treatment effects on progression-free and overall survival. Correlation values close to 1.0 would indicate strong surrogacy.

Results: We identified 2545 eligible patients in 13 randomized trials testing trastuzumab or lapatinib. We collected individual patient data from 1963 patients and retained 1839 patients from 9 trials for analysis (7 first-line trials). During follow-up, 1072 deaths and 1462 progression or deaths occurred. The median survival time was 22 months (95% CI 21-23 months) and the median progression-free survival was 5.7 months (95% CI 5.5-6.1 months). At the individual level, the Spearman correlation was equal to $\rho=0.67$ (95% CI 0.66 to 0.67) corresponding to a squared correlation value of 0.45. At the trial level, the squared correlation between treatment effects (log hazard ratios) on progression-free and overall survival was provided by $R^2=0.51$ (95% CI 0.22 to 0.81).

Conclusions: In trials of HER2-targeted agents in HER2+ metastatic breast cancer, progression-free survival moderately correlates with overall survival at the individual level and treatment effects on progression-free survival correlate moderately with those on overall mortality, providing only modest support for considering progression-free survival as a surrogate. Progression-free survival does not completely substitute for overall survival in this setting.

Key words: surrogate, progression-free survival, HER2, metastatic breast cancer, trastuzumab, lapatinib

Introduction

Worldwide, approximately 1.68 million new cases of female breast cancer are diagnosed each year and this rate is increasing globally[1]. Approximately 15-30% of these tumors overexpress HER2/neu (human epidermal Growth factor receptor type 2), which is associated with aggressive tumor behavior and poor prognosis[2-4]. Trastuzumab, a monoclonal antibody directed against the extracellular domain of the HER2 tyrosine kinase receptor, has revolutionized HER2-positive (HER2+) breast cancer treatment since its approval by the U.S. Federal Drug Administration in 1998. It is approved for use in both adjuvant[5, 6] and metastatic settings[7] and has been investigated in clinical trials in the neoadjuvant setting[8]. Despite this, a substantial proportion of women will experience a recurrence or progression of their disease, suggesting the presence of de novo resistance or the development of resistance to trastuzumab. This has led to the pursuit and successful development of other molecules, used alone or in combination with trastuzumab or chemotherapy: lapatinib (approved by the Food and Drug Administration (FDA) in 2007) and more recently, pertuzumab (2012) and Trastuzumab-DM1 (2013).

The gold standard endpoint for the evaluation of new therapies in oncology is overall survival (OS). But OS, although simple to measure, easy to interpret and clinically meaningful, has the disadvantage of requiring extended follow-up, and of being confounded by unrelated causes of death or the successive lines of effective therapy now available in common solid tumors. An endpoint that is reached more rapidly may answer the question posed by clinical trials more quickly and, potentially, expedite drug approval. For example in colorectal cancer, disease-free survival (DFS) has been validated as a surrogate for OS in the adjuvant setting[9] and progression-free survival (PFS) has been validated as a surrogate for OS in advanced disease[10]. It should be noted, however, that surrogate endpoints may be specific to a class of agents. In colorectal cancer, DFS and PFS have only been validated for first-line fluoropyrimidine-based regimens, and the extrapolation of surrogacy to other classes of agents having substantially different mechanisms of action may not be warranted.

The preferred approach for surrogate endpoint evaluation is the use of individual patient data (IPD), the reference method against which other forms of systematic review should be measured. Within this framework, a surrogate endpoint may be assessed both at the individual (correlation between endpoints) and trial level (correlation between treatment effects on endpoints). Besides colorectal cancer, this approach has been tested in advanced breast cancer[11], lung cancer[12, 13], head and neck cancer[14], gastric cancer[15, 16] and leukemia[17].

In the advanced setting, PFS has been shown to be an appropriate surrogate for evaluation of chemotherapy effects in several malignancies, but in metastatic breast cancer (MBC), PFS was shown not to be a valid surrogate for overall survival when reanalyzing 3,953 patients in 11 trials that compared an anthracycline (alone or in combination) with a taxane (alone or in combination with an anthracycline)[11]. A literature-based study of 67 trials in MBC of various chemotherapy regimens also suggested an insufficiently high correlation [18]. However, a more recent meta-analysis of the literature found a stronger correlation between treatment effects in trials of HER2-positive MBC, as compared to the HER2-negative population ([19]) so that further evaluation of PFS as a surrogate endpoint of OS is warranted. This study, the first IPD meta-analysis of anti-HER2 agents in MBC, aimed to assess to what extent PFS correlates with, and may be used as a surrogate for OS.

Methods

Protocol

We assessed the endpoints according to the preplanned objective of PFS as a surrogate for OS in MBC patients in trials studying the effect of anti-HER2 treatments and wrote a study protocol (available upon request), which was approved by the medical ethics committee of Jules Bordet Institute. Briefly, a previously conducted electronic literature search[20] was updated using PubMed -using terms 'trastuzumab', 'Herceptin', 'lapatinib', 'Tykerb', 'pertuzumab', 'neratinib', 'Trastuzumab-DM1' and the exploded MeSH term 'breast neoplasms' and search line [(breast or mammary) and (cancer* or tumour* or tumor* or neoplas* or metastas* or carcinoma)]-, clinicaltrials.gov and conference proceedings in April 2011. Eligible publications consisted of randomized controlled trials (phase II or III) that accrued HER2+ MBC patients in 1992-2008. At least one of the study arms had to investigate a HER2-targeted agent. A collaboration was sought with industrial partners (Roche, GSK) for access to IPD from industry-led studies. The protocol requested IPD on survival outcomes and key prognostic factors and prespecified the statistical analysis outlined below.

Statistical analysis

Investigator-assessed PFS was defined as the time from randomization to clinical or radiological progression, or death. Patients who had no documented evidence of events were censored at the date of last follow-up. OS was defined as the time from randomization to death, irrespective of cause.

A correlation approach was used: at the individual level, the rank correlation coefficient ρ between distributions of PFS and OS was assessed with a bivariate survival model that takes censoring into account (Hougaard copula)[21]; at the trial level, the correlation between treatment effects (log hazard ratios) on PFS and OS were quantified through a linear regression model, weighted by trial size. Treatment effects were estimated by Cox regression and by the copula model.

The squared correlation coefficients or coefficients of determination—ie, ρ^2 at the individual level and R^2 at the trial level—were calculated to investigate the amount of variation explained by the surrogate. The candidate surrogate endpoints were deemed acceptable only if both correlation coefficients were close to 1.00. We used a leave-one-trial out strategy to study the sensitivity of the trial-level squared correlation when leaving each trial out once.

The surrogate threshold effect was calculated as the minimum treatment effect on the surrogate that would be necessary to predict a non-zero effect on OS[22]. A future trial would require an upper limit of the confidence interval (CI) for the estimated surrogate treatment effect to fall below the surrogate threshold effect to predict a non-zero effect on OS.

The Kaplan-Meier method was used to construct survival curves. Median follow-up times were calculated by the reversed Kaplan-Meier method. Statistical analyses were done with SAS (version 9.3) and R (version 3.1). All randomized patients were analyzed according to intention to treat.

Results

The search strategy resulted in 2545 eligible patients included in 13 randomized clinical trials testing trastuzumab or lapatinib (see flow chart in supplementary figure 1). Four trials were still in progress or did not have available data so that we collected

and checked individual patient data from 1963 HER2-positive patients included in 9 trials[7, 23-29]. One phase II trial did not have sufficient follow-up data for OS beyond progression[30] leading to a total of 1839 patients included in 8 trials that were retained for analysis. Details of the treatment arms evaluated are provided in Table 1. One trial was a four-arm trial leading to a total of 2 treatment comparisons for targeted HER2-treatments. We will denote the total of 9 treatment comparisons as 'trials' from now on, of which 6 tested trastuzumab and 3 lapatinib. The majority of trials were conducted in the first-line setting (7 out of 9 trials, 1198 patients). The description of the patients included in the 9 trials is provided in Supplementary table 1. A small majority (55% in control, 56% in anti-HER2 arm) of patients were ER-negative. Of note, 552 patients (30%) had been previously exposed to trastuzumab before inclusion in the trials, while the majority of patients had been exposed to chemotherapy.

The median follow-up for OS and PFS were given by respectively 33 months (95% CI 32-34 months) and 28 months (95% CI 26-32 months). During follow-up, 1072 deaths and 1462 PFS events occurred. The median OS was estimated to be 22 months (95% CI 21-23 months) and the median PFS was 5.7 months (95% CI 5.5-6.1 months). PFS and OS curves are shown in Figure 1, according to treatment arm. The 1-year PFS probabilities were estimated by 18% (95% CI 16-21%) in the control arm and 30% (95% CI 28-34%) in the anti-HER2 agent arm; while 2-year OS probability estimates were 42% (95% CI 39-46%) in the control arm and 51% (95% CI 47-54%) in the anti-HER2 agent arm.

At the individual level, PFS was moderately correlated with OS (Spearman $\rho=0.67$, 95% CI 0.67-0.68, or equivalently an R^2 value of 0.45, 95% CI 0.44-0.45). In an exploratory analysis, we restricted the data to those 583 patients included in first-line trials before 1998, the year of FDA approval of trastuzumab. The individual level correlation was estimated to be the same ($\rho=0.67$, 95% CI 0.67-0.68).

At the trial level, treatment effects on PFS correlated moderately with treatments effects on OS: $R^2=0.51$ (95% CI 0.22 to 0.81) using log hazard ratios from Cox models (Figure 2, see also Supplementary figure 2 for forest plots of hazard ratios on PFS and OS). Thus only about half of the variation in weighted treatment effects on OS can be explained by effects on PFS. The surrogate threshold effect, the minimum treatment effect that is necessary on PFS to be able to predict a non-zero effect on OS is provided by 0.72 (graphically this value is the abscissa of the intersection of a horizontal line at hazard ratio of OS equal to 1 and the upper bound of the 95% prediction interval of the regression line). The slope of the weighed linear regression equation is estimated by 0.44 (standard error 0.16) and the intercept by 0.04 (0.08), so that estimated treatment effects on OS are largely attenuated. When using the treatment effects as estimated by the copula model, the weighted R^2 was estimated by $R^2=0.65$ (95% CI 0.40 to 0.90).

In the leave-one-out analysis in which each trial was left out once, the trial-level R^2 values were very sensitive to the exclusion of single trials and ranged from 0.05 to 0.71, with a median R^2 of 0.53. Some additional unplanned exploratory subgroup analyses restricting the data to the set of first-line trials, to ER-positive patients, to ER-negative patients, or excluding borderline HER2+ patients defined by 2+ immunochemistry only, did not lead to substantially better trial-level correlation (data not shown).

Discussion

In the past, surrogate endpoints evaluations of PFS in metastatic breast cancer have revealed mixed results. The interpretation of the findings of 3 studies is limited as they extracted data from published literature[18, 19, 31]. In contrast, one study evaluated individual patient data from 3953 patients included in 11 randomized clinical trials that compared an anthracycline with a taxane[11]. PFS was shown not to be a valid surrogate for OS (individual level $\rho=0.69$ and trial-level squared correlation $R^2=0.23$). However, it is known that a surrogate endpoint needs to be evaluated for classes of drugs since the mechanism of action can be different.

In this study we explored whether in a more biologically homogenous defined group of patients (HER2+) the surrogacy of PFS for OS may be higher for targeted anti-HER2 cancer therapies. Using the gold standard method to study trial-level surrogacy - i.e. through collection of individual patient data- we included 1839 patients from 9 trials in the analyses. PFS was shown to be moderately correlated with OS at the individual level (Spearman correlation $\rho=0.67$, 95% CI 0.67 to 0.68) and treatments effects (log hazard ratios) on PFS correlated moderately with treatment effects on OS ($R^2=0.51$, 95% CI 0.22 to 0.81). Of note, our estimated individual level correlation (0.67) was almost identical to the estimated individual level correlation in the metastatic trials of anthracycline vs. taxane (0.69). As far as treatment effects were concerned, to the best of our knowledge there is no formal consensus on the minimum trial-level R^2 value needed to validate a surrogate endpoint and several authors have used different cut-offs (from 0.60 ([32, 33]) to 0.72 ([34]) and 0.75 ([13, 35])). No matter what cut-off is chosen, based on the current results we cannot accept PFS as validated surrogate for OS. Similarly, the surrogate threshold effect is estimated to be 0.72 so that a very strong treatment effect on PFS needs to be obtained before a non-zero effect on OS can be predicted.

The lack of stronger correlation between PFS and OS for HER2-targeted agents in HER2+ MBC could be related to the crossover that was allowed in several of the included trials, the administration of 2nd or 3th-line treatments and the relatively long post-progression time[36], a feature not common to the studies of other malignancies where PFS has been validated as surrogate for OS (i.e. advanced colorectal cancer[10], locally advanced lung cancer[13], locally advanced head and neck cancer[14]). In the trials included in the current study, only scarce information on crossover was collected excluding a potential trial-level evaluation taking crossover into account. Just as in colorectal cancer where several strategy trials have already been conducted[37], the objective of future trials in MBC could consist in identifying the optimal treatment sequence across lines of therapy instead of the best first-line treatment. For this purpose, crossover has to be incorporated in the design of the trial.

It may seem important to highlight the controversies on the effect of bevacizumab on PFS and OS in MBC. In a re-analysis of the individual patient data of 3 phase III trials in the first-line setting ($n=2447$), adding bevacizumab to standard chemotherapy prolonged PFS (HR=0.64, 95% CI 0.57-0.71) but did not significantly improve OS (HR=0.97, 95% CI 0.86–1.08)[38]. In 2011, the FDA withdrew its authorization for bevacizumab in MBC after the initial accelerated approval of 2008. The use of surrogate endpoints in trials should not be used as an excuse for not performing long-term follow-up, which is necessary to control unexpected adverse reactions and also to get sufficient power to analyze OS. The use of the surrogate endpoint would allow one to conclude more rapidly on the treatment effect, but this should not lead to prematurely stop patient follow-up.

Recently, some additional phase III trials studying the effect of HER2-targeted agents in this setting have been conducted (in particular with pertuzumab, trastuzumab-DM1 but also a couple of studies with lapatinib or trastuzumab)[39-42]. These were not eligible when our protocol was set-up and accrued patients after our cut-off date of 2008. It may thus be of interest to update the current analysis in a future research collaboration. However, it seems rather unlikely that the degree of surrogacy of PFS for OS would increase because there likely were more effective 2nd-and 3th-line options available in the recent trials as compared to the historical ones. The recent trials may potentially have more precise recordings of treatments received after progression for fine-tuned analyses of crossover, although it is still not the norm in oncology clinical trials to systematically collect this information.

In summary, the current findings provide only modest support for considering PFS as a surrogate for OS in HER2+ metastatic breast cancer; PFS does not completely substitute for OS in this setting. It can however be problematic to use OS as primary endpoint for a first-line therapy trial in metastatic breast cancer because of crossover, 2nd-line treatments and competing risk of deaths.

Acknowledgements

We are grateful to the study investigators and the two pharmaceutical companies (Roche, GSK) for having provided access to the individual patient data of the randomized clinical trials for this academic project.

Funding

Ligue Nationale Contre le Cancer

Disclosure

MP, FPL: consultancy honoraria for Roche and GSK

JS: research funding/honorarium for Roche and GSK

ADL: consultancy honoraria for GSK

GvM: research grants by Roche and GSK

MC: DSMB member for 2 GSK studies and chair the SystHERs steering committee (Roche)

All remaining authors have declared no conflicts of interest

References

1. Torre LA, Bray F, Siegel RL et al. Global cancer statistics, 2012. *CA Cancer J Clin* 2015; 65: 87-108.
2. Slamon DJ, Clark GM, Wong SG et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. *Science* 1987; 235: 177-182.
3. Ravdin PM, Chamness GC. The c-erbB-2 proto-oncogene as a prognostic and predictive marker in breast cancer: a paradigm for the development of other macromolecular markers--a review. *Gene* 1995; 159: 19-27.
4. Slamon DJ, Godolphin W, Jones LA et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. *Science* 1989; 244: 707-712.
5. Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. *N Engl J Med* 2005; 353: 1659-1672.

6. Romond EH, Perez EA, Bryant J et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. *N Engl J Med* 2005; 353: 1673-1684.
7. Kaufman B, Mackey JR, Clemens MR et al. Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study. *J Clin Oncol* 2009; 27: 5529-5537.
8. Baselga J, Bradbury I, Eidtmann H et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTT0): a randomised, open-label, multicentre, phase 3 trial. *Lancet* 2012; 379: 633-640.
9. Sargent DJ, Wieand HS, Haller DG et al. Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials. *J Clin Oncol* 2005; 23: 8664-8670.
10. Buyse M, Burzykowski T, Carroll K et al. Progression-free survival is a surrogate for survival in advanced colorectal cancer. *Journal of Clinical Oncology* 2007; 25: 5218-5224.
11. Burzykowski T, Buyse M, Piccart-Gebhart MJ et al. Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer. *J Clin Oncol* 2008; 26: 1987-1992.
12. Laporte S, Squifflet P, Baroux N et al. Prediction of survival benefits from progression-free survival benefits in advanced non-small-cell lung cancer: evidence from a meta-analysis of 2334 patients from 5 randomised trials. *BMJ Open* 2013; 3.
13. Mauguen A, Pignon JP, Burdett S et al. Surrogate endpoints for overall survival in chemotherapy and radiotherapy trials in operable and locally advanced lung cancer: a re-analysis of meta-analyses of individual patients' data. *Lancet Oncol* 2013; 14: 619-626.
14. Michiels S, Le Maître A, Buyse M et al. Surrogate endpoints for overall survival in locally advanced head and neck cancer: meta-analyses of individual patient data. *The Lancet Oncology* 2009; 10: 341-350.
15. Oba K, Paoletti X, Alberts S et al. Disease-free survival as a surrogate for overall survival in adjuvant trials of gastric cancer: a meta-analysis. *J Natl Cancer Inst* 2013; 105: 1600-1607.
16. Paoletti X, Oba K, Bang YJ et al. Progression-free survival as a surrogate for overall survival in advanced/recurrent gastric cancer trials: a meta-analysis. *J Natl Cancer Inst* 2013; 105: 1667-1670.
17. Buyse M, Michiels S, Squifflet P et al. Leukemia-free survival as a surrogate end point for overall survival in the evaluation of maintenance therapy for patients with acute myeloid leukemia in complete remission. *Haematologica* 2011; 96: 1106-1112.
18. Sherrill B, Amonkar M, Wu Y et al. Relationship between effects on time-to-disease progression and overall survival in studies of metastatic breast cancer. *Br J Cancer* 2008; 99: 1572-1578.
19. Petrelli F, Barni S. Surrogate endpoints in metastatic breast cancer treated with targeted therapies: an analysis of the first-line phase III trials. *Med Oncol* 2014; 31: 776.
20. Harris CA, Ward RL, Dobbins TA et al. The efficacy of HER2-targeted agents in metastatic breast cancer: a meta-analysis. *Ann Oncol* 2011; 22: 1308-1317.
21. Burzykowski T, Molenberghs G, Buyse M et al. Validation of surrogate end points in multiple randomized clinical trials with failure time end points. *Journal of the Royal Statistical Society: Series C (Applied Statistics)* 2001; 50: 405-422.
22. Burzykowski T, Buyse M. Surrogate threshold effect: an alternative measure for meta-analytic surrogate endpoint validation. *Pharm Stat* 2006; 5: 173-186.

23. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. *N Engl J Med* 2001; 344: 783-792.
24. Vogel CL, Cobleigh MA, Tripathy D et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. *J Clin Oncol* 2002; 20: 719-726.
25. Marty M, Cognetti F, Maraninchi D et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. *J Clin Oncol* 2005; 23: 4265-4274.
26. von Minckwitz G, du Bois A, Schmidt M et al. Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study. *J Clin Oncol* 2009; 27: 1999-2006.
27. Cameron D, Casey M, Press M et al. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. *Breast Cancer Res Treat* 2008; 112: 533-543.
28. Johnston S, Pippen J, Pivot X et al. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. *J Clin Oncol* 2009; 27: 5538-5546.
29. Di Leo A, Gomez HL, Aziz Z et al. Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer. *J Clin Oncol* 2008; 26: 5544-5552.
30. Gasparini G, Gion M, Mariani L et al. Randomized Phase II Trial of weekly paclitaxel alone versus trastuzumab plus weekly paclitaxel as first-line therapy of patients with Her-2 positive advanced breast cancer. *Breast Cancer Res Treat* 2007; 101: 355-365.
31. Hackshaw A, Knight A, Barrett-Lee P, Leonard R. Surrogate markers and survival in women receiving first-line combination anthracycline chemotherapy for advanced breast cancer. *Br J Cancer* 2005; 93: 1215-1221.
32. Ciani O, Buyse M, Garside R et al. Meta-analyses of randomized controlled trials show suboptimal validity of surrogate outcomes for overall survival in advanced colorectal cancer. *J Clin Epidemiol* 2015; 68: 833-842.
33. Lassere MN, Johnson KR, Schiff M, Rees D. Is blood pressure reduction a valid surrogate endpoint for stroke prevention? An analysis incorporating a systematic review of randomised controlled trials, a by-trial weighted errors-in-variables regression, the surrogate threshold effect (STE) and the Biomarker-Surrogacy (BioSurrogate) Evaluation Schema (BSES). *BMC Med Res Methodol* 2012; 12: 27.
34. IQWiG. Validity of surrogate endpoints in oncology: executive summary. In *IQWiG Reports*. Cologne: IQWiG 2011.
35. Lassere MN, Johnson KR, Boers M et al. Definitions and validation criteria for biomarkers and surrogate endpoints: development and testing of a quantitative hierarchical levels of evidence schema. *J Rheumatol* 2007; 34: 607-615.
36. Broglio KR, Berry DA. Detecting an overall survival benefit that is derived from progression-free survival. *J Natl Cancer Inst* 2009; 101: 1642-1649.
37. Asmis T, Berry S, Cosby R et al. Strategies of sequential therapies in unresectable metastatic colorectal cancer: a meta-analysis. *Curr Oncol* 2014; 21: 318-328.

38. Miles DW, Dieras V, Cortes J et al. First-line bevacizumab in combination with chemotherapy for HER2-negative metastatic breast cancer: pooled and subgroup analyses of data from 2447 patients. *Ann Oncol* 2013; 24: 2773-2780.
39. Verma S, Miles D, Gianni L et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. *N Engl J Med* 2012; 367: 1783-1791.
40. Guan Z, Xu B, DeSilvio ML et al. Randomized trial of lapatinib versus placebo added to paclitaxel in the treatment of human epidermal growth factor receptor 2-overexpressing metastatic breast cancer. *J Clin Oncol* 2013; 31: 1947-1953.
41. Swain SM, Kim SB, Cortes J et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. *Lancet Oncol* 2013; 14: 461-471.
42. Peddi PF, Hurvitz SA. Ado-trastuzumab emtansine (T-DM1) in human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer: latest evidence and clinical potential. *Ther Adv Med Oncol* 2014; 6: 202-209.

Table 1: Retained randomized clinical trials evaluating trastuzumab (T) or lapatinib (L) in HER2-positive metastatic breast cancer of which individual patient data was analyzed, in chronological order

Reference	Treatment comparison	Accrual Period	Phase	# HER2-positive patients	Line of treatment
Slamon et al[43]	Ctl: A+C or P Exp: A+C+T or P+T	1995-1997	III	469	First-line
Vogel et al[44]	Ctl: T (schedule 1) Exp: T (schedule 2)	1995-1998	II	114	First-line
Marty et al[45]	Ctl: D Exp: D+T	2000-2002	II	188	First-line
Kaufman et al[46]	Ctl: Anas Exp: Anas+ T	2001-2004	III	208	First-line
Johnston et al[47]	Ctl: Let+Placebo Exp: Let + L	2003-2006	III	219	First-line
von Minckwitz et al[48]	Ctl: X Exp: X+ T	2003-2007	III	151	Second or subsequent line
Cameron et al[49]	Ctl: X Exp: X + L	2004-2005	III	399	Second or subsequent line
Di Leo et al[50]	Ctl: P Exp: P+L	2004-2005	III	91	First-line

Ctl: Control arm; Exp: Experimental arm

A; Anthracycline; C: Cyclophosphamide; P: Paclitaxel; T: Trastuzumab; D: Docetaxel; Anas: Anastrozole; Let: Letrozole; L: Lapatinib; X: Capecitabine

Figure legends


Fig1: Kaplan-Meier curves of progression-free and overall survival in in HER2-positive metastatic breast cancer according to treatment arm.

Number of patients still at risk below the figure correspond to overall survival.

Fig2: Correlation between treatment effects on progression-free survival (PFS) and overall survival (OS) in the assessment of targeted HER2-agents in metastatic breast cancer

Each trial is represented by a circle, with a size proportional to the number of patients. A logarithmic scale is used on both axes. The plot displays the treatment effects estimated by Cox models. The regression line is weighted by trial size.

Figure 1



		No. At Risk					
		0	6	12	18	24	30
OS, control		926	717	519	371	266	196
OS, anti-HER2 agent		913	735	561	420	312	215

Figure 2

